We describe stepwise protocols measuring the mitochondrial respiration of mouse and human neutrophils and HL60 cells using the metabolic extracellular flux analyzer.
Neutrophils are the first line of defense and the most abundant leukocytes in humans. These effector cells perform functions such as phagocytosis and oxidative burst, and create neutrophil extracellular traps (NETs) for microbial clearance. New insights into the metabolic activities of neutrophils challenge the early concept that they primarily rely on glycolysis. Precise measurement of metabolic activities can unfold different metabolic requirements of neutrophils, including the tricarboxylic acid (TCA) cycle (also known as the Krebs cycle), oxidative phosphorylation (OXPHOS), pentose phosphate pathway (PPP), and fatty acid oxidation (FAO) under physiological conditions and in disease states. This paper describes a step-by-step protocol and prerequirements to measure oxygen consumption rate (OCR) as an indicator of mitochondrial respiration on mouse bone marrow-derived neutrophils, human blood-derived neutrophils, and the neutrophil-like HL60 cell line, using metabolic flux analysis on a metabolic extracellular flux analyzer. This method can be used for quantifying the mitochondrial functions of neutrophils under normal and disease conditions.
Mitochondria play a major role in cell bioenergetics, which generates adenosine triphosphate (ATP) by oxidative phosphorylation (OXPHOS). In addition to this, the role of mitochondria extends into the generation and detoxification of reactive oxygen species, cytoplasmic and mitochondrial matrix calcium regulation, cellular synthesis, catabolism, and the transport of metabolites within the cell1. Mitochondrial respiration is essential in all cells, as their dysfunction can result in metabolic problems2, including cardiovascular diseases3 and a wide variety of neurodegenerative diseases, such as age-related macular degeneration4, Parkinson's and Alzheimer's diseases5, and Charcot-Marie-Tooth disease 2 A (CMT2A)6.
Electron microscopic studies on neutrophils revealed there are relatively few mitochondria7, and they rely heavily on glycolysis for their energy production as mitochondrial respiration rates are very low8. However, mitochondria are crucial for neutrophil functions, such as chemotaxis9 and apoptosis10,11,12. A previous study revealed a complex mitochondrial network in human neutrophils with high membrane potential. The mitochondrial membrane potential loss is an early indicator of neutrophil apoptosis10. Treatment with mitochondrial uncoupler carbonyl cyanide m-chlorophenyl hydrazone (CCCP) showed significant inhibition in chemotaxis, along with a change in mitochondrial morphology9,10.
Although the primary energy source for neutrophils is glycolysis, mitochondria provide the ATP that initiates neutrophil activation by fueling the first phase of purinergic signaling, which boosts Ca2+ signaling, amplifies mitochondrial ATP production, and initiates neutrophil functional responses13. Dysfunction of the mitochondrial respiratory chain results in excessive production of toxic reactive oxygen species (ROS) and leads to pathogenic damages14,15,16. NETosis, which is the process of forming neutrophil extracellular traps (NETs), is a critical property of neutrophils that helps them fight against pathogens17 and contributes to many pathological conditions, including cancer, thrombosis, and autoimmune disorders18. Mitochondrial-derived ROS contribute to NETosis19, mitochondrial DNA can be a component of NETs18, and altered mitochondrial homeostasis impairs NETosis20,21,22,23,24. Furthermore, during normal differentiation or maturation, neutrophil metabolic reprogramming gets reversed by limiting glycolytic activity, and they engage in mitochondrial respiration and mobilize intracellular lipids25,26.
The metabolic extracellular flux analyzer can continuously monitor and quantify live cell mitochondrial respiration and glycolysis. The analyzer utilizes a 96-well plate format sensor cartridge and two fluorophores to quantify oxygen (O2) concentration and pH changes. The sensor cartridge is above the cell monolayer during the assay and forms a ~200 nm high microchamber. The optical fiber bundles in the analyzer are used to excite the fluorophores and detect the fluorescent intensity changes. Real-time changes in O2 concentration and pH are automatically calculated and shown as oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). There are four ports on the sensor cartridge that allow loading up to four compounds into each well during the assay measurements. This protocol focuses on quantifying the mitochondrial respiration of mouse and human neutrophils, as well as the neutrophil-like HL60 cells, using the metabolic extracellular flux analyzer.
Heparinized whole-blood samples were obtained from healthy human donors after obtaining informed consent, as approved by the Institutional Review Board of UConn Health in accordance with the Declaration of Helsinki. All animal experiments followed the UConn Health Institutional Animal Care and Use Committee (IACUC) guidelines, and approval for the use of rodents was obtained from the UConn Health IACUC according to criteria outlined in the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health. Male C57BL/6 mice at 6 weeks of age were used in this study.
1. Preparation of the 96-well plate for the metabolic extracellular flux assay
2. Preparation and seeding of cells
Figure 1: Schematic diagram of the isolation of bone marrow cells and neutrophils. (A) Harvesting bone marrow cells from a mouse and (B) isolating neutrophils from human blood. Please click here to view a larger version of this figure.
Cell type | Cells per well | Compounds/Reagents | Working solution concentration | Injection volume to ports | Final concentration in wells |
Mouse neutrophils | 2 × 105 | Oligomycin | 25 µM | 20 µL | 2.5 µM |
FCCP | 7.5 µM | 17.6 µL | 0.61 µM | ||
Rotenone Antimycin A mixture | 10 µM | 24 µL | 1 µM | ||
Human neutrophils | 4 × 105 | Oligomycin | 10 µM | 20 µL | 1 µM |
FCCP | 12.5 µM | 22 µL | 1.25 µM | ||
Rotenone Antimycin A mixture | 10 µM | 24 µL | 1 µM | ||
Undifferentiated or differentiated HL60 cells | 2.5 × 105 | Oligomycin | 25 µM | 20 µL | 2.5 µM |
FCCP | 15 µM | 22 µL | 1.5 µM | ||
Rotenone Antimycin A mixture | 10 µM | 24 µL | 1 µM |
Table 1: Cell numbers and reagent concentrations for the mitochondrial stress test.
3. Preparing compounds in the mitochondrial stress test kit
Figure 2: The mitochondrial stress assay cartridge and their ports of injection. The image shows the cartridge of the mitochondrial stress assay and an enlarged image showing the loading of individual drugs/medium to the ports. Abbreviation: FCCP = carbonylcyanide p-trifluoromethoxy phenylhydrazone. Please click here to view a larger version of this figure.
4. Running the mitochondrial stress assay
Representative OCR dynamics are shown indicating the mitochondrial respiration changes in response to oligomycin, FCCP, and rotenone/antimycin A mixture of mouse neutrophils (Figure 3A), human neutrophils (Figure 3B), and undifferentiated and differentiated HL60 cells (Figure 3C). In all cells, oligomycin treatment decreases the OCR value by inhibiting the proton channel of ATP synthase; FCCP treatment restores the OCR value by increasing the flow of electrons and oxygen consumption to maintain the membrane potential and achieve maximal respiration; and rotenone/antimycin A mixture treatment eliminates mitochondrial respiration by blocking complexes I and III of the electron transport chain.
We observed that after neutrophil-directed differentiation, HL60 cells showed decreased mitochondrial respiration (Figure 3C). After quantifying different respiration parameters, mentioned above, differentiated HL60 cells showed significantly lower basal mitochondrial (Figure 4B) respiration, proton leak-linked respiration (Figure 4C), ATP-linked respiration (Figure 4D), and non-mitochondrial respiration (Figure 4G). Maximal respiration (Figure 4E) in differentiated HL60 cells was increased, but not significantly. The spare respiratory capacity (Figure 4F) was significantly increased.
Figure 3: Representative graphs showing the dynamic changes of OCR during the mitochondrial stress test assay. (A) Mean ± SD from n = 3 replicates of mouse neutrophils. (B) Mean ± SD from n = 3 replicates of human neutrophils. (C) Mean ± SD from n = 3 replicates of undifferentiated (HL60, blue) and differentiated (dHL60, red) HL60 cells. Abbreviation: OCR = oxygen consumption rate. Please click here to view a larger version of this figure.
Figure 4: Respiration parameters obtained from OCR dynamics. (A) Schematic showing how to calculate (a) basal mitochondrial respiration, (b) proton leak-linked respiration, (c) ATP-linked respiration, (d) maximal respiration, (e) spare respiratory capacity, and (f) non-mitochondrial respiration. (B–G) Mean ± SD of n = 3; (B) basal mitochondrial respiration, (C) proton leak-linked respiration, (D) ATP-linked respiration, (E) maximal respiration, (F) spare respiratory capacity, and (G) non-mitochondrial respiration of undifferentiated (HL60) and differentiated (dHL60) HL60 cells. ns (non-significant) p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by unpaired Student's t-test. Please click here to view a larger version of this figure.
The standard procedure that measures the mitochondrial respiration of neutrophils using the metabolic extracellular flux analyzer is limited by many factors, including cell number, cell growth, and viability. Each compound concentration varies among the type and source of cells in this assay. Oligomycin and rotenone/antimycin A are mostly used in a similar concentration among most cell types. However, as the FCCP-induced maximum respiratory rate varies among different cells, careful titration of FCCP is required to optimize the concentration42. It is also better to perform sequential additions of FCCP during the optimization. Although the metabolic extracellular flux analyzer injects the drugs into the plate under air pressure43, the impermeability of the cell membrane to some mitochondrial complex inhibitors limits their use in the case of intact cells in comparison to isolated mitochondria44. The loading into the ports has to be carefully performed to avoid cross-contamination. The substrate concentration (e.g., glucose, pyruvate, glutamine) in the medium may also influence mitochondrial activity and needs to be optimized.
Apart from the drug concentrations, the cell seeding density is also a critical parameter in obtaining a good OCR value. Optimal cell seeding density varies by cell type, and it is recommended to use different seeding densities in preliminary experiments to test the efficacy of the measurement. Accurate cell counting is mandatory for lowering the variability between groups, and the appropriate coating materials for the culture plate must be tested to ensure the adherence of cells at the bottom of the plate. Centrifugation of the culture plate with a speed of 300 × g at RT for 5 min without brake helps the quick sedimentation and attachment of the cells. Before seeding the cells, sufficient washing is desirable after aspirating the coating material.
The seeding of cells is performed by pipetting cells at the bottom edge, to avoid edge effects and to ensure uniform spreading of the cells45. The cells are maintained at 37 °C and allowed to rest for at least 1 hr to minimize the edge effect46. Maintaining them in a non-CO2 incubator to degas the cell culture plate before measurement is recommended since the level of oxygen in the gas mixture can differ according to the experiment and cell type, with different hypoxia values for different tissues and cell types47. The assay medium must be prepared on the day of the assay (70 mL of medium is sufficient for the assay). Normalization of the data with the cell number can be performed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2,5-tetrazolium bromide (MTT) assay, the nuclear fragmentation assay with Hoechst, the cell counting assay, or protein or DNA quantification assays48. Since different mitochondrial inhibitors are used, cell viability needs to be considered as a factor for the result. It is recommended to perform a cell viability test at the end of the assay to rule out a possible cytotoxic effect of the drugs used.
In addition to OCR, the metabolic extracellular flux analyzer can also measure ECAR, which is commonly used in quantifying glycolysis49. However, in the mitochondrial stress assay, ECAR values reflect the acidity generated by both glycolysis and the tricarboxylic acid cycle (via CO2) in mitochondrial respiration. To measure glycolysis, a glycolysis stress test kit is recommended. Initially, the OCR prior to the addition of the compounds shows the basal respiration of the neutrophils. Basal respiration occurs due to the protons transported from the mitochondrial matrix to the intermembrane space passing through the inner mitochondrial membrane, depending on the inner mitochondrial membrane composition. Basal respiration accounts for ~30%-50% of the metabolic rate of resting cells1,50.
Calculations based on the basal respiration of the assay could reduce the variability among groups and types of cells. Normalization of the data has been achieved by comparison to the basal respiration without the addition of any drugs, which allows normalizing changes depending on cell count and bench error on the assay. Spare respiratory capacity is the difference between maximal OCR and basal OCR and is an indicator of how close the cells are functioning to their bioenergetic limit. A decrease in maximal respiration indicates reduced electron transport in the respiratory chain from complexes I and II to complexes III and IV, and eventually to molecular oxygen. Figure 4A shows the schematic representation of the calculations of the assay.
The increase in spare respiratory capacity indicates that cells can respond well to further energy demands, which is a prerequisite in the case of neutrophils as they end up in respiratory burst on activation51,52,53,54,55. However, ECAR data of the mitochondrial stress assay cannot represent the glycolysis rate of the neutrophils. Certain assessments can be made on the data; for example, the reduction in ECAR values in both mouse and human neutrophils after the addition of rotenone and antimycin A implies that the ECAR values before the addition of these complex I and III inhibitors are primarily due to CO2 production from the TCA cycle. In the case of cell lines, the ECAR values are constant after the addition of rotenone and antimycin A, suggesting the ECAR values before the addition are due to glycolysis45.
Mitochondrial disorders are clinical conditions characterized by faulty OXPHOS. In the case of neutrophils, measurement of the OCR is low due to no cell proliferation, low mitochondrial count, and early senescence56. In neurodegenerative disorders, neutrophils extravasate into amyloid-β (Aβ) deposit areas. The Aβ42 peptide triggers integrin activation and rapid neutrophil adhesion57. During apoptosis, neutrophil mitochondria release proapoptotic proteins into the cytosol58. It is also shown that the neutrophil migration speed is reduced, and chemotaxis is abolished when treated with CCCP9. This suggests the potential role of mitochondria and mitochondrial respiration in neutrophil function. Mitochondrial activities in diverse cell types under many pathological conditions have been reported and linked to pathogenesis, such as Alzheimers5, schizophrenia59, chronic respiratory diseases60, bipolar disorders, sepsis, diabetics, asthma, pulmonary hypertension, and sickle cell disease. Emerging therapies, such as improving respiratory chain flux by using antioxidants (e.g., CoQ10, idebenone, alpha-lipoic acid, vitamin C and E), and/or cofactors (e.g., riboflavin, thiamine), and the administration of mitochondrial substrates such as L-carnitine, have been used in treating mitochondrial disorders. However, these treatments are not standardized and may not be effective61. A noninvasive standardized methodology, such as using the metabolic extracellular flux analyzer, to quantify mitochondrial functions in disease-relevant cells, such as neutrophils, could serve as a diagnostic biomarker in therapeutics.
The authors have nothing to disclose.
We acknowledge Dr. Anthony T. Vella and Dr. Federica Aglianoin from the Department of Immunology at UConn Health for their training in using the metabolic extracellular flux analyzer, and Dr. Lynn Puddington in the Department of Immunology at UConn Health for her support of the instruments. We acknowledge Dr. Geneva Hargis from UConn School of Medicine for her help with scientific writing and editing of this manuscript. This research was supported by grants from the National Institutes of Health, National Heart, Lung, and Blood Institute (R01HL145454), National Institute of General Medical Sciences (R35GM147713 and P20GM139763), a startup fund from UConn Health, and a Career re-entry fellowship from the American Association of Immunologists.
37 °C non-CO2 incubator | Precision | Economy Model 2EG | Instrument |
Biorender | Software Application | ||
Centrifuge | Eppendorf | Model 5810R | Instrument |
Corning Cell-Tak Cell and Tissue Adhesive | Corning | 102416-100 | Reagent |
EasySep Magnet | STEMCELL | 18000 | Magnet |
EasySepMouse Neutrophil Enrichment kit | STEMCELL | 19762A | Reagents |
Graphpad Prism 9 | Software Application | ||
Human Serum Albumin Solution (25%) | GeminiBio | 800-120 | Reagents |
Ketamine (VetaKet) | DAILYMED | NDC 59399-114-10 | Anesthetic |
PBS | Cytiva | SH30256.01 | Reagents |
Plate buckets | Eppendorf | UL155 | Accessory |
PolymorphPrep | PROGEN | 1895 (previous 1114683) | polysaccharide solution |
Purified mouse anti-human CD18 antibody | Biolegend | 302102 | Clone TS1/18 |
RPMI 1640 Medium | Gibco | 11-875-093 | Reagents |
Seahorse metabolic extracellular flux analyzer | Agilent | XFe96 | Instrument |
Seahorse XF Cell Mito Stress Test Kit | Agilent | 103015-100 | mitochondrial stress test Kit |
Swing-bucket rotor | Eppendorf | A-4-62 | Rotor |
Vactrap 2 Vacum Trap | Fox Lifesciences | 3052101-FLS | Instrument |
Wave | Software Application | ||
XF 1.0 M Glucose Solution | Agilent | 103577-100 | Reagent |
XF 100 mM Pyruvate Solution | Agilent | 103578-100 | Reagent |
XF 200 mM Glutamine Solution | Agilent | 103579-100 | Reagent |
XF DMEM medium | Agilent | 103575-100 | Reagent |
XFe96 FluxPak | Agilent | 102601-100 | Material |
Xylazine (AnaSed Injection) | DAILYMED | NDC 59399-110-20 | Anesthetic |